CTRI/2020/03/023789已完成Unknown
Prescriber Based, Active Post Marketing Surveillance Study (PMS) to Generate TheSafety & Efficacy Data Of Diazepam and Propranolol in The Treatment of Chronic Anxiety & Insomniain Actual Field Conditions Of Use.
AN Pharmacia Laboratories Pvt ltd1 个研究点 分布在 1 个国家目标入组 200 人开始时间: 2020年9月3日最近更新:
试验速览
- 阶段
- Unknown
- 状态
- 已完成
- 发起方
- 入组人数
- 200
- 试验地点
- 1
- 主要终点
- Assessment based on HAMA scale, Clinician Global Impression (CGI) and Patient Global Impression (PGI) scales
研究概览
简要总结
Prescriber Based, Active Post Marketing Surveillance Study (PMS) to Generate The Safety
& Efficacy Data Of Diazepam and Propranolol in The Treatment of Chronic Anxiety & Insomnia in Actual
Field Conditions Of Use.
Primary Objective:
The primary objective of this PMS trial is to find out safety &tolerability of the product in patient with Chronic Anxiety and Insomniaâ€
Secondary Objective:
The secondaryobjective of this PMS trial is to find out efficacy of the product by clinicianglobal assessment.
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18.00 Year(s) 至 65.00 Year(s)（—）
- 性别
- All
入选标准
- •Both Male and Female patient.
- •Ages: > 18 years and < 65 years.
- •Patients with Chronic Anxiety and Insomnia.
- •Confirmed diagnosis of primary insomnia (as defined by the Diagnostic and Statistical Manual for Mental Disorders-IV [DSM-IV-TR]) present at the time of evaluation for at least 3 months
- •Baseline Hamilton Rating Scale for Anxiety (HAMA) scores ≥18
- •Women of child bearing age willing to take contraceptive measure to prevent pregnancy during the study
- •Patients willing to give written informed consent.
排除标准
- •History of hypersensitivity to the study drugs
- •Chronic heart failure, respiratory failure or chronic liver and renal failure.
- •Patient with active cancer
- •Female who is pregnant, planning a pregnancy (during the course of the study) or nursing a child
- •Certain medications that may interfere with the study medication and worsen the patient condition (these will be identified by the study Investigator).
- •Patients with a history of chronic hepatitis B or C infection, HIV infection.
结局指标
主要结局
Assessment based on HAMA scale, Clinician Global Impression (CGI) and Patient Global Impression (PGI) scales
时间窗: 14 days
次要结局
- Evaluate efficacy of this FDC in treatment of Chronic Anxiety and Insomnia.(14 days)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
不适用
Post Marketing Surveillance Study to Observe Safety and Effectiveness of NEPHOXIL ® in S. Korea PatientsHyperphosphatemiaNCT06186934Kyowa Kirin Korea Co., Ltd.600
招募中
不适用
Post Marketing Surveillance Study to Observe Safety and Effectiveness of CRYSVITA® in S. Korean PatientsFGF23-related Hypophosphataemic Rickets and OsteomalaciaNCT06202027Kyowa Kirin Korea Co., Ltd.100
已完成
不适用
Lyrica (Pregabalin) Korean Post Marketing Surveillance StudyNeuropathic PainPost-market SurveillanceEpilepsyFibromyalgiaNCT01220180Pfizer's Upjohn has merged with Mylan to form Viatris Inc.4,175
已完成
不适用
Primovist Regulatory Post Marketing Surveillance (PMS)LiverNCT00924248Bayer4,358
已完成
不适用
Angeliq Regulatory Post Marketing SurveillancePostmenopausal PeriodOsteoporosis, PostmenopausalNCT01064453Bayer4,078